Inhibrx Biosciences (NASDAQ:INBX) Stock, Quote.Headers.trade-ideas

Inhibrx Biosciences

Inhibrx

Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.

Titoli a dividendo scelti dai migliori analisti di Wall Street

Long Ideas

News

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

APEI

INBX

OLED

Around $2M Bet On Franklin Resources? Check Out These 4 Stocks Executives Are Buying

Wall Street US stocks

HNRG

TCBI

Over $7M Bet On This Health Care Stock? Check Out These 3 Stocks Executives Are Buying

Health care cost illustration

EXAS

TDOC

Top 4 Health Care Stocks That Are Preparing To Pump This Month

Inhibrx Biosciences Inc

Inhibrx Inc COM

Loop Capital analyst Chris Dankert maintains Regal Rexnord (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRX#NYSE">RRX</a>) with a Buy and maintains $200 price target.

Price Target

Analyst Ratings

Loop Capital Maintains Buy on Regal Rexnord, Maintains $200 Price Target

WIIM

DASH

DoorDash shares are trading higher after BTIG upgraded the stock from Neutral to Buy and announced a $155 price target.

The United States is rapidly falling behind China in preparing for potential conflict, as revealed in recent hearings at the Pentagon. 
What Happened: Two key congressional panels heard that the Pentagon&#8217;s outdated procedures and a crisis-driven public are significant obstacles. Lawmakers from both parties urged Deputy Secretary of State Kurt Campbell to address these issues, the South China Morning Post<a href="https://www.scmp.com/news/china/diplomacy/article/3279059/us-falling-rapidly-behind-china-preparing-next-war-two-congressional-panels-hear?module=top_story&amp;pgtype=homepage"> reported</a> on Wednesday.
House Foreign Affairs Committee chairman Michael McCaul criticized the slow pace of technology transfers to allies, despite legislation intended to expedite the process. Campbell agreed, stating adjustments are necessary for stronger partnerships with Great Britain and Australia.
Democratic congressman Gabe Amo also expressed concerns about delays, to which Campbell responded that contract reviews are the primary cause. He assured that the U.S. would provide essential resources to its allies.
The hearings occurred amid budget disagreements and a delayed defense roadmap. The Commission on the National Defence Strategy&#8217;s recent report called for a larger military and closer ties with allies to counter threats from China, Russia, Iran, and North Korea.
Former congresswoman Jane Harman and former undersecretary of defense Eric Edelman highlighted the need for a more integrated force and a modernized industrial base. Edelman warned of the potential for a global conflict and the risk of losing such a war.
See Also: <a href="https://www.benzinga.com/news/24/09/40894933/kim-jong-uns-north-korea-outranks-china-as-russias-top-ally-in-ukraine-conflict-says-military-intell?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Kim Jong Un&#8217;s North Korea Outranks China As Russia&#8217;s Top Ally In Ukraine Conflict, Says Military Intelligence Chief</a>
Campbell emphasized the importance of technology in competition and the need for more tech-savvy personnel in the government. Both committees stressed the significance of alliances to counter China&#8217;s growing influence.
Why It Matters: The warnings from congressional panels come amid escalating tensions between the United States and China. Recently, China's ambassador to the United States, Xie Feng,<a href="https://www.benzinga.com/news/24/09/40851594/chinese-ambassador-issues-stern-warning-to-us-on-red-lines-taiwan-question-is-the-most-paramount-and"> issued a stern warning</a> to the U.S. regarding interference in China&#8217;s sovereignty, particularly concerning Taiwan. He emphasized that Taiwan is a critical &#8220;red line&#8221; that must not be crossed.
Additionally, the U.S. and its allies have raised alarms over <a href="https://www.benzinga.com/news/24/09/40827572/us-and-allies-raise-alarm-over-chinas-support-for-russias-military">China's support for Russia's military</a>, which is seen as a significant factor in the ongoing conflict in Ukraine. This support includes exports of dual-use goods and battlefield items, which are bolstering Russia's military capabilities.
Earlier this year, McCaul warned that the U.S. House Foreign Affairs Committee has the <a href="https://www.benzinga.com/news/24/05/39037174/us-lawmaker-warns-to-declare-war-on-china-in-case-of-an-unprovoked-attack-on-taiwan">authority to declare war</a> if China attacks Taiwan without provocation. He emphasized that deterrence is crucial to prevent such an outcome, stating, &#8220;If the island in an unprovoked manner was invaded, then it would be to the American people and the United States Congress, and my committee that has the power to declare war, how to deal with that.&#8221;
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40915796/japan-expresses-serious-concerns-as-chinese-aircraft-carrier-enters-contiguous-waters-amid-rising-te?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Japan Expresses &#8216;Serious Concerns&#8217; As Chinese Aircraft Carrier Enters Contiguous Waters Amid Rising Tensions: &#8216;Utterly Unacceptable&#8217;</a></li>
</ul>
Image via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Politics

Global

General

US Lagging Behind China In War Preparedness, Congressional Panels Warn

Loop Capital analyst Yun Kim maintains Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) with a Hold and maintains $270 price target.

Loop Capital Maintains Hold on Salesforce, Maintains $270 Price Target

Loop Capital analyst Mark Schappel maintains Aspen Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZPN#NASDAQ">AZPN</a>) with a Buy and raises the price target from $204 to $260.

AZPN

Loop Capital Maintains Buy on Aspen Technology, Raises Price Target to $260

Full Fiscal Year 2025:
Endava expects revenue will be in the range of &pound;800.0 million to &pound;810.0 million, representing a constant currency revenue increase of between&nbsp;10.0%&nbsp;and&nbsp;11.5%&nbsp;on a year over year basis. Endava expects adjusted diluted EPS to be in the range of &pound;1.12 to &pound;1.17 per share.
This above&nbsp;guidance&nbsp;for the&nbsp;first quarter&nbsp;and full fiscal year 2025 assumes the exchange rates on August 31, 2024 (when the exchange rate was 1 British Pound to 1.31 US Dollar and 1.19 Euro).

Earnings

Guidance

DAVA

Endava Expects FY2025 Revenue Of £800M-£810M Versus Consensus Of £742.01M, Sees Adjusted EPS Of £1.12-£1.17

Stephens &amp; Co. analyst Jim Salera reiterates Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) with a Equal-Weight and maintains $159 price target.

Reiteration

Stephens & Co. Reiterates Equal-Weight on Darden Restaurants, Maintains $159 Price Target

Biotech

Health Care

BTAI

Bioxcel Therapeutics Will Reduce Its Workforce By 15 Employees, Or Approximately 28% Of The Company's Headcount-Filing

First Quarter&nbsp;Fiscal Year 2025:
Endava expects revenue will be in the range of &pound;194.0 million to &pound;195.0 million, representing a constant currency revenue increase of between&nbsp;4.5%&nbsp;and&nbsp;5.0%&nbsp;on a year over year basis. Endava expects adjusted diluted EPS to be in the range of &pound;0.21 to &pound;0.22 per share.
Full Fiscal Year 2025:
Endava expects revenue will be in the range of &pound;800.0 million to &pound;810.0 million, representing a constant currency revenue increase of between&nbsp;10.0%&nbsp;and&nbsp;11.5%&nbsp;on a year over year basis. Endava expects adjusted diluted EPS to be in the range of &pound;1.12 to &pound;1.17 per share.
This above&nbsp;guidance&nbsp;for the&nbsp;first quarter&nbsp;and full fiscal year 2025 assumes the exchange rates on August 31, 2024 (when the exchange rate was 1 British Pound to 1.31 US Dollar and 1.19 Euro).

Endava Expects Q1 2025 Revenue Of £194M-£195M Versus Consensus Of £195.668M, Sees Adjusted EPS Of £0.21-£0.22

Chinese e-commerce juggernaut Alibaba Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>), also considered a barometer for the country's tech industry, is up in Thursday's premarket trading following the U.S. Federal Reserve lowering its benchmark interest rate to spur demand.
The U.S. Fed slashed the lending rate by 50 bps, lowering the central bank's benchmark rate to between 4.75% and 5%
Alibaba's domestic peers PDD Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>), JD.com, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>), and Baidu, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) stocks are also up.
<a target="_blank" href="https://in.benzinga.com/markets/equities/24/09/40932103/it-stocks-on-the-rise-after-u-s-fed-cuts-interest-rate" rel="noreferrer noopener">Analysts expect the interest</a> rate cut to drive growth in discretionary spending from U.S. companies. It could also boost Chinese companies that are invested in integrating capital-intensive artificial intelligence technology into their different businesses, including e-commerce, logistics, cloud, and more, to drive growth despite the U.S. sanctions on advanced technology.
Beaten-down Chinese electric vehicle stocks, including NIO Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>), XPeng Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>), Li Auto Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>), and ZEEKR Intelligent Technology Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZK#NYSE">ZK</a>), are also up Thursday. AI technology is also an indispensable part of their progress.
Meanwhile, China <a target="_blank" href="https://www.benzinga.com/government/24/09/40923879/chinas-ymtc-makes-strides-in-chip-production-substitutes-asml-lam-research-tech-as-us-sanctions-bite" rel="noreferrer noopener">needs help finding</a> solutions to the U.S. technology embargo through domestic chipmakers like Yangtze Memory Technologies Co. However, Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) AI chips are still making their way into China via illegal routes and tweaking other countries' export rules.
Meanwhile, Alibaba's cloud unit will host its annual tech event, Aspara Conference 2024, to discuss the future of artificial general intelligence (AGI). Key speakers at the event include Alibaba and cloud unit chief Eddie Wu Yongming and XPeng founder He Xiaopeng, SCMP <a target="_blank" href="https://www.scmp.com/tech/big-tech/article/3279005/alibaba-cloud-kick-annual-aspara-tech-event-focus-ai?module=perpetual_scroll_0&amp;pgtype=article" rel="noreferrer noopener">reports</a>. Autonomous driving and humanoid robots will be major topics at the Aspara main forum. Moonshot AI, StepFun, and Shengshu Technology AI start-ups will likely share their large language model (LLM) experiences.
Alibaba showcased 100 open-source artificial intelligence models catering to applications and sectors ranging from automobiles to gaming and science research, CNBC <a target="_blank" href="https://www.cnbc.com/2024/09/19/alibaba-launches-over-100-new-ai-models-releases-text-to-video-generation.html" rel="noreferrer noopener">cites</a> Alibaba from the event.
The <a target="_blank" href="https://www.benzinga.com/news/24/09/40901862/whats-going-on-with-chinese-ev-stocks-nio-xpeng-li-auto-zeekr-on-tuesday" rel="noreferrer noopener">Chinese stocks got</a> a boost earlier this week from reports indicating People's Bank of China's (PBOC) plans to cut the bank reserve requirement ratio (RRR) by 50 bps, followed by another half-point cut in the first half of 2025.
Price Actions: BABA stock is up 4.11% at $87.89 premarket at last check Thursday. PDD is up 3.27% at $101.44, JD is up 6.50% at $28.67, BIDU is up 3.40% at $87.55, NIO is up 4.78% at $5.25, XPEV is up 5.79% at $9.14, LI is up 2.75% at $21.33, ZK is up 3.63% at $15.71.
Photo via Shutterstock

Government

Regulations

Emerging Markets

Movers

Tech

Media

BABA

BIDU

NVDA

Citigourp Global Markets 2% Protected Notes Linked To The Djia

XPEV

What's Going On With Chinese Tech Stocks Like Alibaba, PDD On Thursday?

The program aims to re-engage patients with the healthcare system, delivering essential care to underserved communities in Sacramento, San Diego, Riverside, Los Angeles, San Bernadino, and Orange County through a partnership with a top 10 national insurance provider.

DCGO

DocGo ExpandsProgram To Enhance Healthcare Access For California Medi-Cal Enrollees/Patients/Members

Stock Split

ARQQ

Arqit Quantum Has Determined To Effect A 25:1 Reverse Share Split, Effective September 25

Endava (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAVA#NYSE">DAVA</a>) reported quarterly earnings of &pound;0.22 per share&nbsp;a 61.4 percent decrease over earnings of &pound;0.57 per share from the same period last year. The company reported quarterly sales of &pound;194.418 million which missed the analyst consensus estimate of &pound;195.668 million by 0.64 percent. This is a 2.44 percent increase over sales of &pound;189.791 million the same period last year

Endava Q4 2024 Adj. EPS £0.22 May Not Be Comparable To £22.62 Estimate, Sales £194.418M Miss £195.668M Estimate

Per the terms of the Proposed Acquisition, Psyence Biomed will issue to Psyence Group shares of its common stock valued at&nbsp;$1.1 million&nbsp;dollars, at a price of&nbsp;$0.55&nbsp;per share, in exchange for Psyence Group&#39;s&nbsp;11.13%&nbsp;stake in PsyLabs.

Psyence Biomedical Enters Agreement With Psyence Group For Acquisition Of 11.13% Stake In Privately-held PsyLabs For About $1.1M

Roth MKM analyst Matt Koranda downgrades Vista Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSTO#NYSE">VSTO</a>) from Buy to Neutral and maintains the price target from $42 to $42.

Downgrades

VSTO

Roth MKM Downgrades Vista Outdoor to Neutral, Maintains Price Target to $42

Bioxcel Therapeutics Announced Its Clinical Prioritization, While Deprioritizing Sales Efforts For Its Approved Drug Igalmi (Dexmedetomidine) Sublingual Film. The Company Plans To Maintain Igalmi In The Market Without Its Current Commercial Infrastructure

Roth MKM analyst Scott Fortune initiates coverage on Turning Point Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPB#NYSE">TPB</a>) with a Buy rating and announces Price Target of $50.

Initiation

Roth MKM Initiates Coverage On Turning Point Brands with Buy Rating, Announces Price Target of $50

Larimar Therapeutics, Inc. - Common Stock

LRMR

Larimar Therapeutics Announced That Data From Its Nomlabofusp Phase 1 Studies And Phase 2 Dose Exploration Study, Some Of Which Has Been Previously Disclosed, Will Be Presented At The Annual International Congress For Ataxia Research

HC Wainwright &amp; Co. analyst Robert Burns upgrades Prelude Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRLD#NASDAQ">PRLD</a>) from Neutral to Buy and announces $5 price target.

Upgrades

PRLD

HC Wainwright & Co. Upgrades Prelude Therapeutics to Buy, Announces $5 Price Target

B. Riley Securities analyst Madison El-Saadi initiates coverage on WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) with a Buy rating and announces Price Target of $11.

B. Riley Securities Initiates Coverage On WAVE Life Sciences with Buy Rating, Announces Price Target of $11

Inhibrx Biosciences Inc (INBX) just unveiled an update. Inhibrx Biosciences, Inc. has made its latest corporate presentation available to the publi...

Inhibrx Biosciences Shares Latest Corporate Presentation Update

Inhibrx Biosciences Inc (INBX) has received a new Hold rating, initiated by JMP Securities analyst, Reni Benjamin. Reni Benjamin has given his Hold...

Inhibrx Biosciences: Hold Rating Justified by Financial Stability and Clinical Pipeline Potential

Inhibrx Biosciences Inc (INBX) has issued an update. Inhibrx has updated its corporate presentation on its website, providing an essential resource...

Inhibrx Biosciences Reveals Updated Corporate Presentation

JMP Securities analyst Reni Benjamin maintained a Hold rating on Inhibrx Biosciences Inc (INBX – Research Report) today. The company's shares close...

JMP Securities Remains a Hold on Inhibrx Biosciences Inc (INBX)

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Inhibrx Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/inbx-stock-quote/">INBX</a>) just reported results for the second quarter of 2024.<ul><li>Inhibrx Biosciences reported earnings per share of $125.48. This was above the analyst estimate for EPS of -$1.47.</li><li>The company reported revenue of $100,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/inbx-stock-earnings-inhibrx-biosciences-for-q2-of-2024/">INBX Stock Earnings: Inhibrx Biosciences Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

INBX Stock Earnings: Inhibrx Biosciences Beats EPS for Q2 2024

Inhibrx Biosciences, Inc. GAAP EPS of $125.40, revenue of $100M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Inhibrx (NASDAQ:<a href="https://investorplace.com/stock-quotes/inbx-stock-quote/">INBX</a>) just reported results for the first quarter of 2024.<ul><li>Inhibrx reported earnings per share of -$1.44. This was above the analyst estimate for EPS of -$1.51.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/inbx-stock-earnings-inhibrx-for-q1-of-2024/">INBX Stock Earnings: Inhibrx Beats EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

INBX Stock Earnings: Inhibrx Beats EPS for Q1 2024

Inhibrx gains after insider purchases from CEO

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Inhibrx (NASDAQ:<a href="https://investorplace.com/stock-quotes/inbx-stock-quote/">INBX</a>) just reported results for the first quarter of 2024.<ul><li>Inhibrx reported earnings per share of -$1.44. This was above the analyst estimate for EPS of -$1.51.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div>	The post <a href="https://investorplace.com/earning-results/2024/08/inbx-stock-earnings-inhibrx-for-q1-of-2024/">INBX Stock Earnings: Inhibrx Beats EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2024 Update

AAPL

ACHC

ADBE

ADPT

AMZN

AVGO

BBIO

BMRN

DDOG

DLTR

EWTX

FDMT

FERG

LBPH

MSFT

NAMS

NFLX

ORIC

PEPG

PHVS

ROIV

RPRX

TMUS

TRVI

TTWO

VKTX

WDAY

Press Releases

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates TAST, MDC, INBX

Penny Stocks

TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - HMST, FREE, EVBG, INBX

Legal

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates INBX, HAYN, EVBG, KAMN

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates WRK, TGAN, ANSS, INBX

Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger

INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWN, INBX, AVRO

Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off

Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi

Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

ANSS

AVRO

EVBG

FREE

HAYN

HMST

KAMN

TAST

TGAN

Abeona Therapeutics

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Akebia Therapeutics

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Inhibrx Biosciences

Inhibrx Biosciences (INBX) Forecast

Inhibrx Biosciences (NASDAQ:INBX) Stock, Quote.Headers.trade-ideas